• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Orchard Therapeutics plc

    2/5/24 2:39:49 PM ET
    $ORTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ORTX alert in real time by email
    15-12G 1 d731893d1512g.htm 15-12G 15-12G
    OMB APPROVAL  
    OMB Number:   3235-0167   
    Expires:   July 31, 2024   
    Estimated average burden  
    hours per response   1.50   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38722

     

     

    ORCHARD THERAPEUTICS PLC

    (Exact name of registrant as specified in its charter)

     

     

    245 Hammersmith Road, London W6 8PW, United Kingdom; +44 (0) 203 808-8286

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    American Depositary Shares, each representing one ordinary share, nominal value £0.10 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

       ☒

    Rule 12g-4(a)(2)

       ☐

    Rule 12h-3(b)(1)(i)

       ☒

    Rule 12h-3(b)(1)(ii)

       ☐

    Rule 15d-6

       ☐

    Rule 15d-22(b)

       ☐

    Approximate number of holders of record as of the certification or notice date: One (1) holder

    Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date:   

    February 5, 2024

         By:   

    /s/ Frank E. Thomas, President and Chief Operating Officer

     

    SEC 2069 (08-11)   Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

    Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

     

     

     

    Get the next $ORTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORTX

    DatePrice TargetRatingAnalyst
    12/29/2021$12.00 → $9.00Overweight
    Cantor Fitzgerald
    11/16/2021Neutral → Underweight
    JP Morgan
    11/5/2021$15.00 → $13.00Outperform
    Oppenheimer
    8/18/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ORTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Orchard Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $9.00 from $12.00 previously

      12/29/21 7:21:48 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Orchard Therapeutics from Neutral to Underweight

      11/16/21 5:23:39 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Orchard Therapeutics with a new price target

      Oppenheimer reiterated coverage of Orchard Therapeutics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      11/5/21 9:48:29 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

      TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the

      5/7/24 7:00:17 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

      TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b

      5/3/24 7:00:38 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

      Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de

      3/20/24 7:00:07 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Orchard Therapeutics plc

      15-12G - Orchard Therapeutics plc (0001748907) (Filer)

      2/5/24 2:39:49 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:05 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:12 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care